CDK2 and cancer: The anticancer potential of the major chemical compound (3-Isobutylhexahydropyrrolo[1,2-a]pyrazine-1,4-dione) was first demonstrated by molecular docking analysis with the CDK2 protein and cytotoxicity assays against three cancer cell lines.